FI104255B - Förfarande för framsätllning av fusionsproteiner innehållande N-terminalfragmenter av mänsklig serumalbumin - Google Patents

Förfarande för framsätllning av fusionsproteiner innehållande N-terminalfragmenter av mänsklig serumalbumin Download PDF

Info

Publication number
FI104255B
FI104255B FI915073A FI915073A FI104255B FI 104255 B FI104255 B FI 104255B FI 915073 A FI915073 A FI 915073A FI 915073 A FI915073 A FI 915073A FI 104255 B FI104255 B FI 104255B
Authority
FI
Finland
Prior art keywords
hsa
variant
sequence
polypeptide
terminal
Prior art date
Application number
FI915073A
Other languages
English (en)
Finnish (fi)
Other versions
FI915073A0 (fi
FI104255B1 (sv
Inventor
David James Ballance
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Publication of FI915073A0 publication Critical patent/FI915073A0/fi
Application granted granted Critical
Publication of FI104255B1 publication Critical patent/FI104255B1/sv
Publication of FI104255B publication Critical patent/FI104255B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (5)

1. Ett förfarande för framställning av en fusionspolypeptid omfattande, som ät-minstone en del av dess N-terminala del, en N-terminal del av HSA eller en variant därav och, som ätminstone en del av dess C-terminala del, en annan polypeptid med 5 undantag för att när nämnda N-terminala del av HSA är 1-n-delen, där n är 369-419 eller en en variant därav, sä är nämnda polypeptid (a) 585-1578-delen av humanfib-ronektin eller variant därav, (b) 1-368-delen av CD4 eller en variant därav, (c) plätt-härstammande tillväxtfaktor eller en variant därav, (d) transformerande tillväxtfaktor β eller en variant därav, (e) 1-261-delen av fullt utvecklat humanplasmafibronektin 10 eller en variant därav, (f) 278-578-delen av fullt utvecklat humanplasma-fibronektin eller en variant därav, (g) 1-272-delen av fullt utvecklat human-von Willebrandts faktor eller en variant därav eller (h) alfa-1-antitrypsin eller en variant därav, känne-tecknat av att i en transformerad värdcell uttrycks en polynukleotidsekvens, som kodar nämnda fusionspolypeptid.
2. Förfarande enligt patentkrav 1, kännetecknat av att fusionspolypeptiden des-sutom omfattar ätminstone en N-terminal aminosyra sträckande sig utöver den del som motsvarar den N-terminala delen av HSA. 20
3. Förfarande enligt patentkrav 1 eller 2, kännetecknat av att det finns en spalt- bar region vid kopplingspunkten för nämnda N-terminala eller C-terminala delar av fusionspolypeptid. • I
: 4. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att nämn- 25 da C-terminala del av fusionspolypeptid är 585-1578-delen av humanplasmafibro- : ’ * *i nektin eller varianter därav. ··· • · • · « • · · ··· ·
5. En polynukleotidsekvens uppvisande en nukleotidsekvens anordnad sä att den uttrycker en fusionspolypeptid enligt nägot av föregäende patentkrav. • · · ··· • · · • · · «aa a a a «aa a • a a a a · · a a « a < « « a a « a « « a a i i a a a a a a a a a a i a a a « a a
FI915073A 1989-04-29 1991-10-28 Förfarande för framsätllning av fusionsproteiner innehållande N-terminalfragmenter av mänsklig serumalbumin FI104255B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898909916A GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides
GB8909916 1989-04-29
GB9000650 1990-04-26
PCT/GB1990/000650 WO1990013653A1 (en) 1989-04-29 1990-04-26 Fusion proteins containing n-terminal fragments of human serum albumin

Publications (3)

Publication Number Publication Date
FI915073A0 FI915073A0 (fi) 1991-10-28
FI104255B1 FI104255B1 (sv) 1999-12-15
FI104255B true FI104255B (sv) 1999-12-15

Family

ID=10656000

Family Applications (1)

Application Number Title Priority Date Filing Date
FI915073A FI104255B (sv) 1989-04-29 1991-10-28 Förfarande för framsätllning av fusionsproteiner innehållande N-terminalfragmenter av mänsklig serumalbumin

Country Status (12)

Country Link
EP (1) EP0470165A1 (sv)
JP (1) JP2781459B2 (sv)
KR (1) KR100227167B1 (sv)
AU (1) AU630450B2 (sv)
CA (1) CA2015687C (sv)
FI (1) FI104255B (sv)
GB (2) GB8909916D0 (sv)
HU (1) HUT61049A (sv)
IE (1) IE67651B1 (sv)
IL (1) IL94243A (sv)
WO (1) WO1990013653A1 (sv)
ZA (1) ZA903237B (sv)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
GB9408466D0 (en) * 1994-04-27 1994-06-22 Univ Nottingham Cloning and functional expression of neurotoxins
US5543308A (en) * 1994-10-18 1996-08-06 New England Biolabs, Inc. Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
PE99498A1 (es) * 1996-07-26 1999-01-21 Novartis Ag Polipeptidos de fusion
US5932693A (en) * 1996-12-10 1999-08-03 Washington University Antithrombotic peptides
EP1049790A1 (en) 1998-01-23 2000-11-08 Novo Nordisk A/S Process for making desired polypeptides in yeast
DK1088084T3 (da) 1998-06-15 2007-01-29 Gtc Biotherapeutics Inc Erythropoietin analog-humant serumalbumin fusionsprotein
EP1276756A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
DE60232083D1 (de) 2001-08-15 2009-06-04 Takara Bio Inc Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
EP1496109B1 (en) 2002-03-25 2010-12-08 Takara Bio Inc. Process for producing cytotoxic lymphocyte
WO2005019450A1 (ja) * 2003-08-22 2005-03-03 Takara Bio Inc. 細胞傷害性リンパ球の製造方法
EP2520654B8 (en) 2003-08-26 2017-04-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
EP1831375B1 (en) 2004-12-23 2014-07-16 Novozymes Biopharma DK A/S Gene expression technique
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
JP5670634B2 (ja) 2006-07-13 2015-02-18 アッパートン リミティド タンパク質性物質の粒子の製造方法
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
KR20200044138A (ko) * 2011-06-24 2020-04-28 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
KR20210111245A (ko) * 2018-10-29 2021-09-10 스핀 테라퓨틱스, 엘엘씨 알파-1-항트립신 장애들을 위한 조성물들 및 방법들

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides

Also Published As

Publication number Publication date
EP0470165A1 (en) 1992-02-12
GB8909916D0 (en) 1989-06-14
IL94243A0 (en) 1991-01-31
AU630450B2 (en) 1992-10-29
GB9119043D0 (en) 1991-12-04
HUT61049A (en) 1992-11-30
CA2015687C (en) 2000-08-29
ZA903237B (en) 1991-03-27
IE901554L (en) 1990-10-29
IL94243A (en) 1995-10-31
JPH04506598A (ja) 1992-11-19
CA2015687A1 (en) 1990-10-29
HU904413D0 (en) 1992-01-28
KR100227167B1 (ko) 1999-10-15
WO1990013653A1 (en) 1990-11-15
GB2246783B (en) 1992-10-14
FI915073A0 (fi) 1991-10-28
JP2781459B2 (ja) 1998-07-30
IE67651B1 (en) 1996-04-17
FI104255B1 (sv) 1999-12-15
GB2246783A (en) 1992-02-12
AU5564690A (en) 1990-11-29
KR920701451A (ko) 1992-08-11

Similar Documents

Publication Publication Date Title
FI104255B (sv) Förfarande för framsätllning av fusionsproteiner innehållande N-terminalfragmenter av mänsklig serumalbumin
EP0399666B1 (en) Fusion proteins containing n-terminal fragments of human serum albumin
US5766883A (en) Polypeptides
Kojima et al. Cloning and sequence analysis of cDNA encoding a precursor for rat brain natriuretic peptide
CA1340522C (en) Fusion proteins containing neighbouring histidines for improved purification
US4764504A (en) Novel atrial natriuretic/vasodilator polypeptides
FI104635B (sv) Hirudin producerande transformerad jäst och förfarande för framställning av hirudin med denna
Schaeffer et al. Complete structure of the human transferrin gene. Comparison with analogous chicken gene and human pseudogene
CA1326217C (en) Method for preparing foreign protein in yeast, recombinant dna, transformant
Payne et al. Isolation of the genomic clone for pathogenesis-related protein 1a from Nicotiana tabacum cv. Xanthi-nc
WO1985004870A1 (en) Novel atrial natriuretic/vasodilator polypeptides
FI96966B (sv) Expressionskasett för produktion av en hirudinvariant i jäst, en plasmid innehållande denna, en jästcell transformerad med denna och ett förfarande för framställning av en hirudinvariant med hjälp av jästcellen
Ohsuye et al. Cloning of cDNA encoding a new peptide C-terminal α-amidating enzyme having a putative membrane-spanning domain from Xenopuslaevis skin
IE880928L (en) Vascular anticoagulant proteins
HU211207B (en) Method for producing recombinant dna molecules containing yeart ph05 gene upstream activating sequences
HU204563B (en) Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
HU209146B (en) Method for producing desulphato-hydrudine
AU665034B2 (en) Production of human parathyroid hormone from microorganisms
FI96956C (sv) Förfarande för framställning av ett terapeutiskt användbart hirudinderivat
US5420242A (en) Production of human parathyroid hormone from microorganisms
Barklis et al. Structure of the Dictyostelium discoideum prestalk D11 gene and protein
Hartl et al. The N terminus of laminin A chain is homologous to the B chains
IE890559L (en) A hirudin derivative
Nishikawa et al. Efficient cleavage by α-thrombin of a recombinant fused protein which contains insulin-like growth factor I
AU701136B2 (en) Novel inhibitor

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: NOVOZYMES DELTA LIMITED

Free format text: NOVOZYMES DELTA LIMITED

PC Transfer of assignment of patent

Owner name: NOVOZYMES BIOPHARMA UK LIMITED

Free format text: NOVOZYMES BIOPHARMA UK LIMITED